

Stephen J Kent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6481835/publications.pdf>

Version: 2024-02-01

371
papers

20,176
citations

18436

62
h-index

20307

116
g-index

409
all docs

409
docs citations

409
times ranked

23714
citing authors

#	ARTICLE	IF	CITATIONS
1	Poor protective potential of influenza nucleoprotein antibodies despite wide prevalence. <i>Immunology and Cell Biology</i> , 2022, 100, 49-60.	1.0	9
2	T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination. <i>Journal of Leukocyte Biology</i> , 2022, 111, 355-365.	1.5	25
3	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. <i>Lancet Microbe</i> , The, 2022, 3, e52-e61.	3.4	436
4	Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 210-216.	7.0	486
5	Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles. <i>Science Immunology</i> , 2022, 7, eabf5314.	5.6	38
6	A Quantitative Approach to Unravel the Role of Host Genetics in IgG-Fcγ3R Complex Formation After Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 820148.	2.2	1
7	Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. <i>Nature Immunology</i> , 2022, 23, 768-780.	7.0	41
8	Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil. <i>Journal of Immunology</i> , 2022, , ji2101199.	0.4	6
9	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. <i>Nature Reviews Immunology</i> , 2022, 22, 387-397.	10.6	93
10	The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. <i>Immunity</i> , 2022, 55, 1316-1326.e4.	6.6	38
11	Protein precoating modulates biomolecular coronas and nanocapsule-immune cell interactions in human blood. <i>Journal of Materials Chemistry B</i> , 2022, 10, 7607-7621.	2.9	9
12	SARS-CoV-2-specific T cell memory with common TCRÎ±Î² motifs is established in unvaccinated children who seroconvert after infection. <i>Immunity</i> , 2022, 55, 1299-1315.e4.	6.6	23
13	Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. <i>ACS Nano</i> , 2022, 16, 11769-11780.	7.3	108
14	Immune profiling of influenza-specific B and T cell responses in macaques using flow cytometry-based assays. <i>Immunology and Cell Biology</i> , 2021, 99, 97-106.	1.0	6
15	Influenza B viruses: underestimated and overlooked. <i>Microbiology Australia</i> , 2021, 42, 110-115.	0.1	3
16	CD73+ CD127high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 912.	1.8	2
17	Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. <i>Clinical and Translational Immunology</i> , 2021, 10, e1258.	1.7	28
18	Antibody mediated activation of natural killer cells in malaria exposed pregnant women. <i>Scientific Reports</i> , 2021, 11, 4130.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. <i>Nature Communications</i> , 2021, 12, 1162.	5.8	316
20	Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. <i>Cell Reports</i> , 2021, 34, 108684.	2.9	134
21	Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002142.	3.9	27
22	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100208.	3.3	115
23	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. <i>Nature Communications</i> , 2021, 12, 1403.	5.8	65
24	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	109
25	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
26	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. <i>Nature Communications</i> , 2021, 12, 2037.	5.8	125
27	Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients. <i>Nature Communications</i> , 2021, 12, 2691.	5.8	34
28	CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. <i>Immunity</i> , 2021, 54, 1066-1082.e5.	6.6	106
29	Influence of Poly(ethylene glycol) Molecular Architecture on Particle Assembly and <i>Ex Vivo</i> Particle-Immune Cell Interactions in Human Blood. <i>ACS Nano</i> , 2021, 15, 10025-10038.	7.3	27
30	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 1205-1211.	15.2	3,133
31	Decay of Fc-dependent antibody functions after mild to moderate COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100296.	3.3	56
32	SARS-CoV-2-specific CD8 ⁺ T cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph. <i>Immunology and Cell Biology</i> , 2021, 99, 990-1000.	1.0	28
33	Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria. <i>ELife</i> , 2021, 10, .	2.8	18
34	Quantitatively Tracking Bio-Nano Interactions of Metal-Phenolic Nanocapsules by Mass Cytometry. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 35494-35505.	4.0	9
35	Interactions of core cross-linked poly(2-oxazoline) and poly(2-oxazine) micelles with immune cells in human blood. <i>Biomaterials</i> , 2021, 274, 120843.	5.7	26
36	Plasma Corona Protects Human Immune Cells from Structurally Nanoengineered Antimicrobial Peptide Polymers. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 33821-33829.	4.0	4

#	ARTICLE	IF	CITATIONS
37	Coformulation with Tattoo Ink for Immunological Assessment of Vaccine Immunogenicity in the Draining Lymph Node. <i>Journal of Immunology</i> , 2021, 207, 735-744.	0.4	6
38	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. <i>JCI Insight</i> , 2021, 6, .	2.3	33
39	Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. <i>EBioMedicine</i> , 2021, 70, 103518.	2.7	3
40	From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. <i>Acta Biomaterialia</i> , 2021, 131, 16-40.	4.1	140
41	Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. <i>Journal of Biological Chemistry</i> , 2021, 297, 101065.	1.6	20
42	Influenza lineage extinction during the COVID-19 pandemic?. <i>Nature Reviews Microbiology</i> , 2021, 19, 741-742.	13.6	82
43	A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100386.	3.3	8
44	Immune imprinting and SARS-CoV-2 vaccine design. <i>Trends in Immunology</i> , 2021, 42, 956-959.	2.9	73
45	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. <i>Cell Reports</i> , 2021, 37, 109822.	2.9	35
46	Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots. <i>EBioMedicine</i> , 2021, 72, 103586.	2.7	10
47	Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. <i>European Respiratory Journal</i> , 2021, 57, 2003730.	3.1	100
48	Adaptive immunity to human coronaviruses is widespread but low in magnitude. <i>Clinical and Translational Immunology</i> , 2021, 10, e1264.	1.7	16
49	Stealth nanorods <i>via</i> the aqueous living crystallisation-driven self-assembly of poly(2-oxazoline)s. <i>Chemical Science</i> , 2021, 12, 7350-7360.	3.7	35
50	Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells. <i>Scientific Reports</i> , 2021, 11, 1864.	1.6	4
51	Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	4
52	Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121. <i>Frontiers in Immunology</i> , 2021, 12, 749891.	2.2	4
53	Current and future nanoparticle vaccines for COVID-19. <i>EBioMedicine</i> , 2021, 74, 103699.	2.7	57
54	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. <i>EBioMedicine</i> , 2021, 74, 103729.	2.7	29

#	ARTICLE	IF	CITATIONS
55	Tear antibodies to SARS-CoV-2: implications for transmission. <i>Clinical and Translational Immunology</i> , 2021, 10, e1354.	1.7	15
56	Serological and cellular inflammatory signatures in end-stage kidney disease and latent tuberculosis. <i>Clinical and Translational Immunology</i> , 2021, 10, e1355.	1.7	8
57	Butyrophilin 2A1 is essential for phosphoantigen reactivity by $\hat{I}^{\hat{I}}$ T cells. <i>Science</i> , 2020, 367, .	6.0	275
58	The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. <i>Immunology and Cell Biology</i> , 2020, 98, 253-263.	1.0	42
59	Serum IgA Fc effector functions in infectious disease and cancer. <i>Immunology and Cell Biology</i> , 2020, 98, 276-286.	1.0	44
60	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature Medicine</i> , 2020, 26, 1428-1434.	15.2	400
61	Template-Mediated Assembly of DNA into Microcapsules for Immunological Modulation. <i>Small</i> , 2020, 16, e2002750.	5.2	25
62	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. <i>Nature Reviews Immunology</i> , 2020, 20, 727-738.	10.6	107
63	Person-Specific Biomolecular Coronas Modulate Nanoparticle Interactions with Immune Cells in Human Blood. <i>ACS Nano</i> , 2020, 14, 15723-15737.	7.3	55
64	Understanding the Role of Mucosal-Associated Invariant T-Cells in Non-human Primate Models of HIV Infection. <i>Frontiers in Immunology</i> , 2020, 11, 2038.	2.2	5
65	Block and Lock HIV Cure Strategies to Control the Latent Reservoir. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 424.	1.8	42
66	Controlling the Biological Fate of Micellar Nanoparticles: Balancing Stealth and Targeting. <i>ACS Nano</i> , 2020, 14, 13739-13753.	7.3	30
67	Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. <i>Nature Microbiology</i> , 2020, 5, 1185-1191.	5.9	553
68	Suboptimal SARS-CoV-2-specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24384-24391.	3.3	168
69	Cellular Interactions: Cellular Interactions of Liposomes and PISA Nanoparticles during Human Blood Flow in a Microvascular Network (Small 33/2020). <i>Small</i> , 2020, 16, 2070185.	5.2	1
70	Modulating the Selectivity and Stealth Properties of Ellipsoidal Polymersomes through a Multivalent Peptide Ligand Display. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000261.	3.9	11
71	What Can Gamma Delta T Cells Contribute to an HIV Cure?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 233.	1.8	16
72	Sequencing B cell receptors from ferrets (<i>Mustela putorius furo</i>). <i>PLoS ONE</i> , 2020, 15, e0233794.	1.1	5

#	ARTICLE	IF	CITATIONS
73	High CD26 and Low CD94 Expression Identifies an IL-23 Responsive VÎ2+ T Cell Subset with a MAIT Cell-like Transcriptional Profile. <i>Cell Reports</i> , 2020, 31, 107773.	2.9	32
74	Innate and Adaptive Anti-SIV Responses in Macaque Semen: Implications for Infectivity and Risk of Transmission. <i>Frontiers in Immunology</i> , 2020, 11, 850.	2.2	7
75	Cellular Interactions of Liposomes and PISA Nanoparticles during Human Blood Flow in a Microvascular Network. <i>Small</i> , 2020, 16, e2002861.	5.2	67
76	Meibomian gland dropout is associated with immunodeficiency at HIV diagnosis: Implications for dry eye disease. <i>Ocular Surface</i> , 2020, 18, 206-213.	2.2	10
77	Lowâ€Fouling Fluoropolymers for Bioconjugation and Inâ€...Vivo Tracking. <i>Angewandte Chemie</i> , 2020, 132, 4759-4765.	1.6	22
78	Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults. <i>Vaccine</i> , 2020, 38, 2368-2377.	1.7	10
79	Lowâ€Fouling Fluoropolymers for Bioconjugation and Inâ€...Vivo Tracking. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 4729-4735.	7.2	40
80	Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques. <i>Scientific Reports</i> , 2020, 10, 22077.	1.6	7
81	Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. <i>JCI Insight</i> , 2020, 5, .	2.3	64
82	Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem. <i>PLoS ONE</i> , 2020, 15, e0241649.	1.1	1
83	Sequencing B cell receptors from ferrets (<i>Mustela putorius furo</i>). , 2020, 15, e0233794.		0
84	Sequencing B cell receptors from ferrets (<i>Mustela putorius furo</i>). , 2020, 15, e0233794.		0
85	Sequencing B cell receptors from ferrets (<i>Mustela putorius furo</i>). , 2020, 15, e0233794.		0
86	Sequencing B cell receptors from ferrets (<i>Mustela putorius furo</i>). , 2020, 15, e0233794.		0
87	Short Communication: Effect of Seminal Plasma on Functions of Monocytes and Granulocytes. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 553-556.	0.5	3
88	Moving the HIV vaccine field forward: concepts of protective immunity. <i>Lancet HIV</i> ,the, 2019, 6, e406-e410.	2.1	1
89	Boosting of Markers of FcÎ3 Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 842-852.	0.5	1
90	Differential Roles of Plasma Protein Corona on Immune Cell Association and Cytokine Secretion of Oligomeric and Fibrillar Beta-Amyloid. <i>Biomacromolecules</i> , 2019, 20, 4208-4217.	2.6	16

#	ARTICLE	IF	CITATIONS
91	Impact of HIV-1 viremia or sexually transmitted infection on semen-derived anti-HIV-1 antibodies and the immunosuppressive capacity of seminal plasma. <i>European Journal of Immunology</i> , 2019, 49, 2255-2258.	1.6	1
92	Improving immunological insights into the ferret model of human viral infectious disease. <i>Influenza and Other Respiratory Viruses</i> , 2019, 13, 535-546.	1.5	28
93	Characterization of Key Bio-Nano Interactions between Organosilica Nanoparticles and <i>Candida albicans</i> . <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 34676-34687.	4.0	11
94	Cross-lineage protection by human antibodies binding the influenza B hemagglutinin. <i>Nature Communications</i> , 2019, 10, 324.	5.8	62
95	A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. <i>Cell</i> , 2019, 177, 1136-1152.e18.	13.5	177
96	Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques. <i>Scientific Reports</i> , 2019, 9, 5661.	1.6	14
97	Link between Low-Fouling and Stealth: A Whole Blood Biomolecular Corona and Cellular Association Analysis on Nanoengineered Particles. <i>ACS Nano</i> , 2019, 13, 4980-4991.	7.3	53
98	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 1025.	2.2	37
99	Inducible Bronchus-Associated Lymphoid Tissues (iBALT) Serve as Sites of B Cell Selection and Maturation Following Influenza Infection in Mice. <i>Frontiers in Immunology</i> , 2019, 10, 611.	2.2	40
100	Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of <i>In Vitro</i> versus <i>In Vivo</i> Models. <i>Journal of Virology</i> , 2019, 93, .	1.5	3
101	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
102	Modulating Targeting of Poly(ethylene glycol) Particles to Tumor Cells Using Bispecific Antibodies. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801607.	3.9	38
103	Role of IgG3 in Infectious Diseases. <i>Trends in Immunology</i> , 2019, 40, 197-211.	2.9	123
104	Identification of murine antigen-specific T follicular helper cells using an activation-induced marker assay. <i>Journal of Immunological Methods</i> , 2019, 467, 48-57.	0.6	15
105	MAIT Cells Upregulate $\hat{1}\pm 4\hat{1}^{27}$ in Response to Acute Simian Immunodeficiency Virus/Simian HIV Infection but Are Resistant to Peripheral Depletion in Pigtail Macaques. <i>Journal of Immunology</i> , 2019, 202, 2105-2120.	0.4	36
106	Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 77-84.	1.5	27
107	Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fc γ 3 Receptors: Implications for Measuring Fc Dependent Antibody Functions. <i>Frontiers in Immunology</i> , 2019, 10, 2415.	2.2	35
108	An Inflammatory Story: Antibodies in Tuberculosis Comorbidities. <i>Frontiers in Immunology</i> , 2019, 10, 2846.	2.2	17

#	ARTICLE	IF	CITATIONS
109	Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways. <i>Journal of Virology</i> , 2019, 93, .	1.5	33
110	Functional cure of HIV: the scale of the challenge. <i>Nature Reviews Immunology</i> , 2019, 19, 45-54.	10.6	93
111	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2019, 93, .	1.5	44
112	Immunological basis for enhanced immunity of nanoparticle vaccines. <i>Expert Review of Vaccines</i> , 2019, 18, 269-280.	2.0	97
113	Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem. <i>Journal of Clinical Investigation</i> , 2019, 129, 850-862.	3.9	78
114	Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions. <i>Journal of Virology</i> , 2018, 92, .	1.5	17
115	Human plasma proteome association and cytotoxicity of nano-graphene oxide grafted with stealth polyethylene glycol and poly(2-ethyl-2-oxazoline). <i>Nanoscale</i> , 2018, 10, 10863-10875.	2.8	42
116	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV</i> , the, 2018, 5, e221-e230.	2.1	34
117	HIV Reactivation after Partial Protection by Neutralizing Antibodies. <i>Trends in Immunology</i> , 2018, 39, 359-366.	2.9	6
118	Circulating T _{FH} cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	196
119	Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. <i>Proteomics</i> , 2018, 18, e1700253.	1.3	23
120	Antibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults. <i>Journal of Infectious Diseases</i> , 2018, 217, 12-23.	1.9	37
121	A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge. <i>Journal of Infectious Diseases</i> , 2018, 218, 856-867.	1.9	12
122	Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. <i>Journal of Immunological Methods</i> , 2018, 457, 41-52.	0.6	51
123	Induction of vaginal-resident HIV-specific CD8 T cells with mucosal prime-boost immunization. <i>Mucosal Immunology</i> , 2018, 11, 994-1007.	2.7	41
124	Anti-HIV-1 antibody-dependent cellular cytotoxicity. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 160-166.	1.5	25
125	Ageing in patients with chronic HIV infection: impact of hypercoagulation. <i>AIDS Research and Therapy</i> , 2018, 15, 22.	0.7	4
126	Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , the, 2018, 5, e553-e559.	2.1	19

#	ARTICLE	IF	CITATIONS
127	The Rare Anaphylaxis-Associated Fc γ RIIa3 Exhibits Distinct Characteristics From the Canonical Fc γ RIIa1. <i>Frontiers in Immunology</i> , 2018, 9, 1809.	2.2	7
128	Influence of Charge on Hemocompatibility and Immunoreactivity of Polymeric Nanoparticles. <i>ACS Applied Bio Materials</i> , 2018, 1, 756-767.	2.3	23
129	Minimum information reporting in bio \hat{a} €“nano experimental literature. <i>Nature Nanotechnology</i> , 2018, 13, 777-785.	15.6	455
130	Mucosal-Associated Invariant T Cells Are Depleted and Exhibit Altered Chemokine Receptor Expression and Elevated Granulocyte Macrophage-Colony Stimulating Factor Production During End-Stage Renal Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1076.	2.2	17
131	Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. <i>Viruses</i> , 2018, 10, 333.	1.5	7
132	A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. <i>Nature Communications</i> , 2018, 9, 2669.	5.8	67
133	Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficiency Virus Type 1 Clade C Envelope Vaccine. <i>Human Gene Therapy</i> , 2018, 29, 1011-1028.	1.4	7
134	The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 727-738.	0.5	22
135	Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. <i>Retrovirology</i> , 2018, 15, 58.	0.9	32
136	Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection. <i>Journal of Infectious Diseases</i> , 2018, 218, 1383-1393.	1.9	8
137	Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. <i>Journal of Clinical Investigation</i> , 2018, 129, 182-191.	3.9	69
138	Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery. <i>ACS Nano</i> , 2017, 11, 54-68.	7.3	153
139	Antibody-dependent cellular cytotoxicity and influenza virus. <i>Current Opinion in Virology</i> , 2017, 22, 89-96.	2.6	60
140	Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. <i>Journal of Virology</i> , 2017, 91, .	1.5	21
141	Expanding role for type I Interferons in restricting HIV growth. <i>Immunology and Cell Biology</i> , 2017, 95, 417-418.	1.0	1
142	Dimeric Fc γ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fc γ Receptor Antibodies Induced by the RV144 Vaccine Trial. <i>Journal of Immunology</i> , 2017, 199, 816-826.	0.4	43
143	Charge Has a Marked Influence on Hyperbranched Polymer Nanoparticle Association in Whole Human Blood. <i>ACS Macro Letters</i> , 2017, 6, 586-592.	2.3	27
144	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. <i>Aids</i> , 2017, 31, 1839-1845.	1.0	10

#	ARTICLE	IF	CITATIONS
145	Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection. <i>EBioMedicine</i> , 2017, 19, 119-127.	2.7	30
146	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. <i>Journal of Virology</i> , 2017, 91, .	1.5	14
147	Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1288-1296.	1.4	55
148	Thiol-Reactive Star Polymers Display Enhanced Association with Distinct Human Blood Components. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 12182-12194.	4.0	24
149	Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 345-353.	0.9	12
150	Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 33683-33694.	4.0	18
151	Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2726-2737.	1.4	1
152	Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. <i>Journal of Virology</i> , 2017, 91, .	1.5	10
153	Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. <i>Vaccine</i> , 2017, 35, 6451-6458.	1.7	16
154	HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. <i>Journal of Virology</i> , 2017, 91, .	1.5	59
155	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	45
156	Eradication and Cure of HIV. , 2017, , 931-935.e1.		0
157	A Role for Fc-Mediated Humoral Immunity in Reducing HIV Transmission Rates between HIV Serodiscordant Heterosexual Couples. <i>EBioMedicine</i> , 2017, 26, 2-3.	2.7	1
158	Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein. <i>Frontiers in Immunology</i> , 2017, 8, 5.	2.2	22
159	Cytotoxic CD4 T Cellsâ€™ Friend or Foe during Viral Infection?. <i>Frontiers in Immunology</i> , 2017, 8, 19.	2.2	177
160	HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells. <i>Frontiers in Immunology</i> , 2017, 8, 376.	2.2	26
161	Divergent Expression of CXCR5 and CCR5 on CD4+ T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection. <i>Frontiers in Immunology</i> , 2017, 8, 495.	2.2	11
162	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. <i>Frontiers in Immunology</i> , 2017, 8, 595.	2.2	20

#	ARTICLE	IF	CITATIONS
163	Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. <i>Frontiers in Immunology</i> , 2017, 8, 1883.	2.2	13
164	Fc functional antibodies in humans with severe H7N9 and seasonal influenza. <i>JCI Insight</i> , 2017, 2, .	2.3	39
165	Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field. <i>Current HIV Research</i> , 2017, 15, 202-215.	0.2	28
166	Modulation of innate and adaptive cellular immunity relevant to HIV-1 vaccine design by seminal plasma. <i>Aids</i> , 2017, 31, 333-342.	1.0	13
167	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 17-23.	0.9	17
168	Influenza-Specific Antibody-Dependent Phagocytosis. <i>PLoS ONE</i> , 2016, 11, e0154461.	1.1	51
169	Functional advantage of educated KIR2DL1+ natural killer cells for anti-HIV-1 antibody-dependent activation. <i>Clinical and Experimental Immunology</i> , 2016, 184, 101-109.	1.1	17
170	Dimeric Fc γ 3R Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG. <i>Journal of Immunology</i> , 2016, 197, 1507-1516.	0.4	90
171	HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation. <i>Scientific Reports</i> , 2016, 6, 26478.	1.6	32
172	Human immune cell targeting of protein nanoparticles "caveospheres". <i>Nanoscale</i> , 2016, 8, 8255-8265.	2.8	31
173	Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine. <i>Journal of Virology</i> , 2016, 90, 5724-5734.	1.5	52
174	Cutaneous mucormycosis secondary to penetrative trauma. <i>Injury</i> , 2016, 47, 1383-1387.	0.7	18
175	Twist in the Tail: Escape from HIV Neutralising Antibodies at a Single Site Confers Broad Susceptibility to Others. <i>EBioMedicine</i> , 2016, 12, 14-15.	2.7	1
176	NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1089-1096.	0.5	31
177	The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype. <i>Vaccine</i> , 2016, 34, 5251-5261.	1.7	28
178	Tuning the properties of pH responsive nanoparticles to control cellular interactions in vitro and ex vivo. <i>Polymer Chemistry</i> , 2016, 7, 6015-6024.	1.9	18
179	HIV vaccines moving forward. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 545.	1.5	0
180	What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. <i>EBioMedicine</i> , 2016, 8, 277-290.	2.7	67

#	ARTICLE	IF	CITATIONS
181	Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. <i>Expert Review of Vaccines</i> , 2016, 15, 719-729.	2.0	30
182	Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control. <i>Journal of NeuroVirology</i> , 2016, 22, 498-507.	1.0	10
183	Recombinant influenza virus expressing HIV-1 p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses. <i>Vaccine</i> , 2016, 34, 1172-1179.	1.7	14
184	High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. <i>Virology</i> , 2016, 492, 1-10.	1.1	10
185	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. <i>Journal of Virology</i> , 2016, 90, 2021-2030.	1.5	53
186	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days. <i>PLoS Pathogens</i> , 2016, 12, e1005740.	2.1	21
187	Paradox of Protection: Preferential Recognition of CD4-induced Epitopes by Anti-HIV-1 ADCC Antibodies. <i>EBioMedicine</i> , 2015, 2, 1298-1299.	2.7	0
188	Prime-Boost Vaccination: Impact on the HIV-1 Vaccine Field. , 2015, , 289-313.		1
189	Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?. <i>Frontiers in Immunology</i> , 2015, 6, 265.	2.2	24
190	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days- Implications for HIV Remission. <i>PLoS Pathogens</i> , 2015, 11, e1005000.	2.1	92
191	MAIT cells are depleted early but retain functional cytokine expression in HIV infection. <i>Immunology and Cell Biology</i> , 2015, 93, 177-188.	1.0	90
192	Engineering Poly(ethylene glycol) Particles for Improved Biodistribution. <i>ACS Nano</i> , 2015, 9, 1571-1580.	7.3	148
193	Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis. <i>Journal of Leukocyte Biology</i> , 2015, 97, 599-609.	1.5	15
194	Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. <i>European Journal of Immunology</i> , 2015, 45, 854-864.	1.6	76
195	Trying to cure HIV with immunotherapy: not so simple. <i>Lancet HIV</i> , 2015, 2, e72-e73.	2.1	0
196	Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity. <i>Expert Review of Vaccines</i> , 2015, 14, 1227-1239.	2.0	16
197	Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 253-259.	1.3	0
198	The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. <i>Aids</i> , 2015, 29, 137-144.	1.0	32

#	ARTICLE	IF	CITATIONS
199	Epitope-Specific CD8+T Cell Kinetics Rather than Viral Variability Determine the Timing of Immune Escape in Simian Immunodeficiency Virus Infection. <i>Journal of Immunology</i> , 2015, 194, 4112-4121.	0.4	9
200	Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. <i>Clinical and Experimental Immunology</i> , 2015, 181, 275-285.	1.1	18
201	Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells. <i>Journal of Virology</i> , 2015, 89, 97-109.	1.5	42
202	Antibody-Dependent Effector Functions Against HIV Decline in Subjects Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 529-538.	1.9	28
203	Contemporary HIV Vaccines: Tissue Resident T-Cells and Strategies to Prevent Mucosal Infection. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 1107-1117.	1.0	3
204	Anti-HIV Antibody-Dependent Activation of NK Cells Impairs NKp46 Expression. <i>Journal of Immunology</i> , 2014, 192, 308-315.	0.4	39
205	Polymorphisms and Interspecies Differences of the Activating and Inhibitory FcγRIIIb of <i>Macaca nemestrina</i> Influence the Binding of Human IgG Subclasses. <i>Journal of Immunology</i> , 2014, 192, 792-803.	0.4	41
206	Modeling the Timing of Antiretroviral Drug Administration during HIV Treatment. <i>Journal of Virology</i> , 2014, 88, 14050-14056.	1.5	19
207	Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation. <i>Aids</i> , 2014, 28, 2781-2786.	1.0	20
208	Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity. <i>Aids</i> , 2014, 28, 1859-1870.	1.0	37
209	Toward Improved Influenza Vaccines. <i>Journal of Infectious Diseases</i> , 2014, 209, 4-5.	1.9	2
210	Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques. <i>Journal of Virology</i> , 2014, 88, 13418-13428.	1.5	39
211	The High Cost of Fidelity. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 8-16.	0.5	36
212	Tentative first steps to eradicate latent HIV. <i>Lancet HIV</i> , 2014, 1, e2-e3.	2.1	1
213	NKT cell depletion in humans during early HIV infection. <i>Immunology and Cell Biology</i> , 2014, 92, 578-590.	1.0	34
214	Drug Resistant SIV Strains Carrying Higher-Fidelity K65R and Q151N Reverse Transcriptase Mutations Are Less Fit In Vivo. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A185-A185.	0.5	0
215	Linking Pig-Tailed Macaque Major Histocompatibility Complex Class I Haplotypes and Cytotoxic T Lymphocyte Escape Mutations in Simian Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2014, 88, 14310-14325.	1.5	21
216	HIV-specific antibody-dependent phagocytosis matures during HIV infection. <i>Immunology and Cell Biology</i> , 2014, 92, 679-687.	1.0	29

#	ARTICLE	IF	CITATIONS
217	Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity in Intravenous Immunoglobulin as a Potential Therapeutic Against Emerging Influenza Viruses. <i>Journal of Infectious Diseases</i> , 2014, 210, 1811-1822.	1.9	57
218	Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza Vaccine. <i>Journal of Immunology</i> , 2014, 193, 469-475.	0.4	112
219	The maturation of antibody technology for the HIV epidemic. <i>Immunology and Cell Biology</i> , 2014, 92, 570-577.	1.0	6
220	Downregulation of Interleukin-18-Mediated Cell Signaling and Interferon Gamma Expression by the Hepatitis B Virus e Antigen. <i>Journal of Virology</i> , 2014, 88, 10412-10420.	1.5	49
221	Measuring Turnover of SIV DNA in Resting CD4+ T Cells Using Pyrosequencing: Implications for the Timing of HIV Eradication Therapies. <i>PLoS ONE</i> , 2014, 9, e93330.	1.1	10
222	The role of T cell immunity in HIV-1 infection. <i>Current Opinion in Virology</i> , 2013, 3, 438-446.	2.6	13
223	Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques. <i>Journal of Immunological Methods</i> , 2013, 394, 73-83.	0.6	22
224	Characterisation of macaque testicular leucocyte populations and T-lymphocyte immunity. <i>Journal of Reproductive Immunology</i> , 2013, 100, 146-156.	0.8	28
225	<i>In-vivo</i> stimulation of macaque natural killer T cells with β -galactosylceramide. <i>Clinical and Experimental Immunology</i> , 2013, 173, 480-492.	1.1	14
226	Simian Immunodeficiency Virus Infects Follicular Helper CD4 T Cells in Lymphoid Tissues during Pathogenic Infection of Pigtail Macaques. <i>Journal of Virology</i> , 2013, 87, 3760-3773.	1.5	94
227	Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. <i>Immunology</i> , 2013, 138, 116-123.	2.0	139
228	Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. <i>Vaccine</i> , 2013, 31, 5506-5517.	1.7	17
229	The search for an HIV cure: tackling latent infection. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 614-621.	4.6	61
230	Mechanically Tunable, Self-Adjuvanting Nanoengineered Polypeptide Particles. <i>Advanced Materials</i> , 2013, 25, 3468-3472.	11.1	84
231	Age-Associated Cross-reactive Antibody-Dependent Cellular Cytotoxicity Toward 2009 Pandemic Influenza A Virus Subtype H1N1. <i>Journal of Infectious Diseases</i> , 2013, 208, 1051-1061.	1.9	62
232	Characterization of the Kynurenine Pathway and Quinolinic Acid Production in Macaque Macrophages. <i>International Journal of Tryptophan Research</i> , 2013, 6, IJTR.S11789.	1.0	23
233	Trivalent Live Attenuated Influenza-Simian Immunodeficiency Virus Vaccines: Efficacy and Evolution of Cytotoxic T Lymphocyte Escape in Macaques. <i>Journal of Virology</i> , 2013, 87, 4146-4160.	1.5	17
234	Standard Trivalent Influenza Virus Protein Vaccination Does Not Prime Antibody-Dependent Cellular Cytotoxicity in Macaques. <i>Journal of Virology</i> , 2013, 87, 13706-13718.	1.5	41

#	ARTICLE	IF	CITATIONS
235	Antibody-Dependent Cellular Cytotoxicity Is Associated with Control of Pandemic H1N1 Influenza Virus Infection of Macaques. <i>Journal of Virology</i> , 2013, 87, 5512-5522.	1.5	168
236	Activation of NK cells by HIV-specific ADCC antibodies. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1011-1018.	1.4	14
237	Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity Antibodies in the Absence of Neutralizing Antibodies. <i>Journal of Immunology</i> , 2013, 190, 1837-1848.	0.4	200
238	Short Communication: Antibody Responses to Human Immunodeficiency Virus Envelope from Infections with Multiple Subtypes Utilize the 1F7-Idiotypic Repertoire. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 778-783.	0.5	4
239	Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to "protective" human leukocyte antigen-B alleles in HIV controllers. <i>Aids</i> , 2013, 27, 519-528.	1.0	43
240	Azithromycin: more lethal than chloramphenicol?. <i>Sexual Health</i> , 2013, 10, 179.	0.4	2
241	Induction of SerpinB2 and Th1/Th2 Modulation by SerpinB2 during Lentiviral Infections In Vivo. <i>PLoS ONE</i> , 2013, 8, e57343.	1.1	14
242	HIV-Specific Antibody Immunity Mediated Through NK Cells and Monocytes. <i>Current HIV Research</i> , 2013, 11, 388-406.	0.2	52
243	An "Escape Clock" for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells. <i>PLoS Pathogens</i> , 2012, 8, e1002615.	2.1	21
244	Loss of Control of HIV Viremia Associated with the Fat Malabsorption Drug Orlistat. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 961-962.	0.5	16
245	Long-lived epithelial immunity by tissue-resident memory T (T _{RM}) cells in the absence of persisting local antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 7037-7042.	3.3	522
246	HIV Infection Abrogates the Functional Advantage of Natural Killer Cells Educated through KIR3DL1/HLA-Bw4 Interactions To Mediate Anti-HIV Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2012, 86, 4488-4495.	1.5	50
247	Anti-HIV antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. <i>European Journal of Immunology</i> , 2012, 42, 2771-2781.	1.6	22
248	Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. <i>Journal of Immunological Methods</i> , 2012, 384, 51-61.	0.6	62
249	HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 767-774.	1.3	7
250	Comparison of Influenza and SIV Specific CD8 T Cell Responses in Macaques. <i>PLoS ONE</i> , 2012, 7, e32431.	1.1	10
251	Influence of Cytokines on HIV-Specific Antibody-Dependent Cellular Cytotoxicity Activation Profile of Natural Killer Cells. <i>PLoS ONE</i> , 2012, 7, e38580.	1.1	22
252	Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. <i>Advances in Virology</i> , 2012, 2012, 1-8.	0.5	20

#	ARTICLE	IF	CITATIONS
253	Ex-vivo Î±-Galactosylceramide activation of NKT cells in humans and macaques. <i>Journal of Immunological Methods</i> , 2012, 382, 150-159.	0.6	21
254	Characterisation of simian immunodeficiency virus-infected cells in pigtail macaques. <i>Virology</i> , 2012, 428, 11-20.	1.1	4
255	NK Cell Function and Antibodies Mediating ADCC in HIV-1-Infected Viremic and Controller Patients. <i>Viral Immunology</i> , 2011, 24, 359-368.	0.6	58
256	Activation of NK Cells by ADCC Antibodies and HIV Disease Progression. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 127-131.	0.9	109
257	Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. <i>Virology</i> , 2011, 412, 110-116.	1.1	37
258	Screening and confirmatory testing of MHC class I alleles in pig-tailed macaques. <i>Immunogenetics</i> , 2011, 63, 511-521.	1.2	29
259	Activation of NK Cells by ADCC Responses During Early HIV Infection. <i>Viral Immunology</i> , 2011, 24, 171-175.	0.6	34
260	HIV Vaccine efficacy trial: Glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. <i>Hum Vaccin</i> , 2011, 7, 466-473.	2.4	22
261	Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7505-7510.	3.3	135
262	Replication-Competent Simian Immunodeficiency Virus (SIV) Gag Escape Mutations Archived in Latent Reservoirs during Antiretroviral Treatment of SIV-Infected Macaques. <i>Journal of Virology</i> , 2011, 85, 9167-9175.	1.5	34
263	The future of mucosal HIV vaccines. <i>Microbiology Australia</i> , 2011, 32, 118.	0.1	0
264	Timing of Immune Escape Linked to Success or Failure of Vaccination. <i>PLoS ONE</i> , 2010, 5, e12774.	1.1	13
265	Does Cytolysis by CD8+ T Cells Drive Immune Escape in HIV Infection?. <i>Journal of Immunology</i> , 2010, 185, 5093-5101.	0.4	30
266	AIDS Vaccine for Asia Network (AVAN): Expanding the Regional Role in Developing HIV Vaccines. <i>PLoS Medicine</i> , 2010, 7, e1000331.	3.9	12
267	Evaluation of Recombinant Influenza Virus-Simian Immunodeficiency Virus Vaccines in Macaques. <i>Journal of Virology</i> , 2009, 83, 7619-7628.	1.5	31
268	High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40). <i>Journal of Immunology</i> , 2009, 183, 2827-2836.	0.4	153
269	Rapid Degranulation of NK Cells following Activation by HIV-Specific Antibodies. <i>Journal of Immunology</i> , 2009, 182, 1202-1210.	0.4	103
270	Balancing Reversion of Cytotoxic T-Lymphocyte and Neutralizing Antibody Escape Mutations within Human Immunodeficiency Virus Type 1 Env upon Transmission. <i>Journal of Virology</i> , 2009, 83, 8986-8992.	1.5	2

#	ARTICLE	IF	CITATIONS
271	Complexity of the Inoculum Determines the Rate of Reversion of SIV Gag CD8 T Cell Mutant Virus and Outcome of Infection. <i>PLoS Pathogens</i> , 2009, 5, e1000378.	2.1	10
272	Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection. <i>Journal of Virology</i> , 2009, 83, 7649-7658.	1.5	35
273	Peripheral NKT Cells in Simian Immunodeficiency Virus-Infected Macaques. <i>Journal of Virology</i> , 2009, 83, 1617-1624.	1.5	36
274	Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy. <i>Journal of Virology</i> , 2009, 83, 1501-1510.	1.5	14
275	Substantial envelope-specific CD8 T-cell immunity fails to control siv disease. <i>Virology</i> , 2009, 384, 21-27.	1.1	11
276	Differential patterns of immune escape at Tat-specific cytotoxic T cell epitopes in pigtail macaques. <i>Virology</i> , 2009, 388, 315-323.	1.1	10
277	A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. <i>Biomaterials</i> , 2009, 30, 5178-5186.	5.7	126
278	Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. <i>Vaccine</i> , 2009, 27, 6605-6612.	1.7	38
279	P19-24. Evaluation of recombinant influenza-SIV vaccines in macaques. <i>Retrovirology</i> , 2009, 6, .	0.9	0
280	P17-03. Nanoengineered layer-by-layer capsules as a novel delivery system for HIV vaccines. <i>Retrovirology</i> , 2009, 6, .	0.9	2
281	P09-08. The complexity of the infecting inoculum determines the outcome of infection. <i>Retrovirology</i> , 2009, 6, P121.	0.9	0
282	P09-07. Balancing reversion of CTL and neutralizing antibody escape mutations within HIV-1 Env upon transmission. <i>Retrovirology</i> , 2009, 6, .	0.9	0
283	P10-07. Extremely rapid degranulation of NK cells activated by HIV-specific antibody dependent cellular cytotoxicity. <i>Retrovirology</i> , 2009, 6, .	0.9	1
284	A Protective Vaccine Delivery System for <i>In Vivo</i> T Cell Stimulation Using Nanoengineered Polymer Hydrogel Capsules. <i>ACS Nano</i> , 2009, 3, 3391-3400.	7.3	170
285	Thrombocytopenia Is Strongly Associated With Simian AIDS in Pigtail Macaques. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 374-379.	0.9	16
286	Designing immunity to HIV: manipulating antibody-dependent cellular cytotoxicity antibodies. <i>HIV Therapy</i> , 2009, 3, 633-640.	0.6	0
287	Binding, Internalization, and Antigen Presentation of Vaccine-Loaded Nanoengineered Capsules in Blood. <i>Advanced Materials</i> , 2008, 20, 4698-4703.	11.1	155
288	HIV-1 infection of monocyte-derived macrophages reduces Fc and complement receptor expression. <i>Clinical and Experimental Immunology</i> , 2008, 95, 450-454.	1.1	27

#	ARTICLE	IF	CITATIONS
289	Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques. <i>Virology</i> , 2008, 374, 528-534.	1.1	21
290	Low pre-infection levels and loss of central memory CD4+ T cells may predict rapid progression in SIV-infected pigtail macaques. <i>Virology</i> , 2008, 381, 11-15.	1.1	12
291	Protection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs. <i>Journal of Medical Primatology</i> , 2008, 37, 24-32.	0.3	3
292	Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques. <i>Journal of Medical Primatology</i> , 2008, 37, 69-78.	0.3	12
293	Rates of HIV immune escape and reversion: implications for vaccination. <i>Trends in Microbiology</i> , 2008, 16, 561-566.	3.5	53
294	Delivery of immunotherapy with peptide-pulsed blood in macaques. <i>Virology</i> , 2008, 378, 201-204.	1.1	9
295	CD4+T-cell subsets: what really counts in preventing HIV disease?. <i>Expert Review of Vaccines</i> , 2008, 7, 155-158.	2.0	4
296	Anti-SIV Cytolytic Molecules in Pigtail Macaques. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1127-1131.	0.5	0
297	Quantification of Simian Immunodeficiency Virus Cytotoxic T Lymphocyte Escape Mutant Viruses. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1067-1072.	0.5	11
298	Limited Maintenance of Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8 T-Cell Receptor Clonotypes after Virus Challenge. <i>Journal of Virology</i> , 2008, 82, 7357-7368.	1.5	13
299	Virus-Specific T-Cell Immunity Correlates with Control of GB Virus B Infection in Marmosets. <i>Journal of Virology</i> , 2008, 82, 3054-3060.	1.5	29
300	Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood. <i>PLoS Pathogens</i> , 2008, 4, e1000055.	2.1	46
301	Vaccination and Timing Influence SIV Immune Escape Viral Dynamics In Vivo. <i>PLoS Pathogens</i> , 2008, 4, e12.	2.1	43
302	Robust NK Cell-Mediated Human Immunodeficiency Virus (HIV)-Specific Antibody-Dependent Responses in HIV-Infected Subjects. <i>Journal of Virology</i> , 2008, 82, 5450-5459.	1.5	95
303	CD4+ Target Cell Availability Determines the Dynamics of Immune Escape and Reversion In Vivo. <i>Journal of Virology</i> , 2008, 82, 4091-4101.	1.5	21
304	Natural Host Genetic Resistance to Lentiviral CNS Disease: A Neuroprotective MHC Class I Allele in SIV-Infected Macaques. <i>PLoS ONE</i> , 2008, 3, e3603.	1.1	21
305	The Utility of ADCC Responses in HIV Infection. <i>Current HIV Research</i> , 2008, 6, 515-519.	0.2	52
306	Utility of Human Immunodeficiency Virus Type 1 Envelope as a T-Cell Immunogen. <i>Journal of Virology</i> , 2007, 81, 13125-13134.	1.5	28

#	ARTICLE	IF	CITATIONS
307	Comparative Efficacy of Subtype AE Simian-Human Immunodeficiency Virus Priming and Boosting Vaccines in Pigtail Macaques. <i>Journal of Virology</i> , 2007, 81, 292-300.	1.5	48
308	In Vivo Fitness Costs of Different Gag CD8 T-Cell Escape Mutant Simian-Human Immunodeficiency Viruses for Macaques. <i>Journal of Virology</i> , 2007, 81, 5418-5422.	1.5	29
309	Vaccine-Induced T Cells Control Reversion of AIDS Virus Immune Escape Mutants. <i>Journal of Virology</i> , 2007, 81, 4137-4144.	1.5	34
310	Killing Kinetics of Simian Immunodeficiency Virus-Specific CD8+ T Cells: Implications for HIV Vaccine Strategies. <i>Journal of Immunology</i> , 2007, 179, 4571-4579.	0.4	30
311	The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. <i>Retrovirology</i> , 2007, 4, 7.	0.9	38
312	The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. <i>Hepatology</i> , 2007, 46, 1332-1340.	3.6	48
313	Drug evaluation: DNA/MVA prime-boost HIV vaccine. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 159-67.	2.3	8
314	Prime-Boost Strategies in DNA Vaccines. , 2006, 127, 171-198.		32
315	Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. <i>Vaccine</i> , 2006, 24, 1378-1388.	1.7	42
316	A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. <i>Aids</i> , 2006, 20, 294-297.	1.0	58
317	MHC class I allele frequencies in pigtail macaques of diverse origin. <i>Immunogenetics</i> , 2006, 58, 995-1001.	1.2	37
318	Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines: Implications for Future Trials. <i>Hum Vaccin</i> , 2006, 2, 134-136.	2.4	13
319	Comparative Evaluation of Simian, Simian-Human, and Human Immunodeficiency Virus Infections in the Pigtail Macaque (<i>Macaca nemestrina</i>) Model. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 580-588.	0.5	66
320	Fitness Constraints on Immune Escape from HIV: Implications of Envelope as a Target for Both HIV-Specific T Cells and Antibody. <i>Current HIV Research</i> , 2006, 4, 191-197.	0.2	15
321	CD127 + CCR5 + CD38 +++ CD4 + Th1 Effector Cells Are an Early Component of the Primary Immune Response to Vaccinia Virus and Precede Development of Interleukin-2 + Memory CD4 + T Cells. <i>Journal of Virology</i> , 2006, 80, 10151-10161.	1.5	47
322	Short Communication: Characteristics of Effective Immune Control of Simian/Human Immunodeficiency Virus in Pigtail Macaques. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 27-32.	0.5	1
323	The pigtail macaque MHC class I allele Mane-A*10 presents an immunodominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. <i>Journal of Medical Primatology</i> , 2005, 34, 282-293.	0.3	45
324	Granulocyte contamination dramatically inhibits spot formation in AIDS virus-specific ELISpot assays: Analysis and strategies to ameliorate. <i>Journal of Immunological Methods</i> , 2005, 297, 177-186.	0.6	14

#	ARTICLE	IF	CITATIONS
325	Phenotypic and kinetic analysis of effective simian human immunodeficiency virus-specific T cell responses in DNA- and fowlpox virus-vaccinated macaques. <i>Virology</i> , 2005, 337, 222-234.	1.1	2
326	Enhanced Cellular Immunity in Macaques following a Novel Peptide Immunotherapy. <i>Journal of Virology</i> , 2005, 79, 3748-3757.	1.5	30
327	Comparison of Whole Gene and Whole Virus Scrambled Antigen Approaches for DNA Prime and Fowlpox Virus Boost HIV Type 1 Vaccine Regimens in Macaques. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 292-300.	0.5	8
328	Analysis of Pigtail Macaque Major Histocompatibility Complex Class I Molecules Presenting Immunodominant Simian Immunodeficiency Virus Epitopes. <i>Journal of Virology</i> , 2005, 79, 684-695.	1.5	71
329	Induction of T-Cell Immunity to Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 7728-7737.	1.5	21
330	Rapid Viral Escape at an Immunodominant Simian-Human Immunodeficiency Virus Cytotoxic T-Lymphocyte Epitope Exact a Dramatic Fitness Cost. <i>Journal of Virology</i> , 2005, 79, 5721-5731.	1.5	164
331	Reduced Hepatitis B Virus (HBV)-Specific CD4 + T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2005, 79, 3038-3051.	1.5	76
332	Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. <i>Trends in Microbiology</i> , 2005, 13, 243-246.	3.5	39
333	Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. <i>Vaccine</i> , 2005, 23, 1949-1956.	1.7	29
334	Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. <i>Vaccine</i> , 2005, 23, 4647-4657.	1.7	36
335	Mucosally-administered human simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. <i>Vaccine</i> , 2005, 23, 5009-5021.	1.7	59
336	Genetic influences on HIV infection: implications for vaccine development. <i>Sexual Health</i> , 2005, 2, 53.	0.4	7
337	Vaccines and Vaccine Strategies Against HIV. <i>Current Drug Targets</i> , 2004, 5, 71-88.	1.0	22
338	Efficacy of DNA and Fowlpox Virus Priming/Boosting Vaccines for Simian/Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2004, 78, 13819-13828.	1.5	77
339	Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN γ or IL-12. <i>Vaccine</i> , 2004, 23, 188-197.	1.7	47
340	Decreased Neurotropism of nef Long Terminal Repeat (nef /LTR)-Deleted Simian Immunodeficiency Virus. <i>Journal of NeuroVirology</i> , 2003, 9, 442-451.	1.0	18
341	Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma. <i>Journal of Medical Primatology</i> , 2003, 29, 240-247.	0.3	20
342	Lipopolysaccharide induces biochemical alterations in chicks trained on the passive avoidance learning task. <i>Physiology and Behavior</i> , 2003, 78, 679-688.	1.0	11

#	ARTICLE	IF	CITATIONS
343	Evidence of Recombination between 3' and 5' LTRs in Macaques Inoculated with SIV DNA. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 227-230.	0.5	11
344	Vaccines for HIV in the developing world. <i>Internal Medicine Journal</i> , 2002, 32, 136-137.	0.5	0
345	Chimeric Human Papilloma Virus-Simian/Human Immunodeficiency Virus Virus-like-Particle Vaccines: Immunogenicity and Protective Efficacy in Macaques. <i>Virology</i> , 2002, 301, 176-187.	1.1	63
346	Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques. <i>Immunological Reviews</i> , 2001, 183, 94-108.	2.8	7
347	Attenuated and Wild-Type HIV-1 Infections and Long Terminal Repeat-Mediated Gene Expression from Plasmids Delivered by Gene Gun to Human Skin ex Vivo and Macaques in Vivo. <i>Virology</i> , 2001, 287, 71-78.	1.1	9
348	Nucleic Acid Vaccines Tasks and Tactics. <i>Immunologic Research</i> , 2001, 24, 225-244.	1.3	13
349	Simian immunodeficiency virus infections in vervet monkeys (<i>Chlorocebus aethiops</i>) at an Australian zoo. <i>Australian Veterinary Journal</i> , 2001, 79, 406-408.	0.5	1
350	Vaccination with Attenuated Simian Immunodeficiency Virus by DNA Inoculation. <i>Journal of Virology</i> , 2001, 75, 11930-11934.	1.5	31
351	Vaccines for HIV. <i>Expert Opinion on Therapeutic Patents</i> , 2000, 10, 1179-1188.	2.4	3
352	A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. <i>Vaccine</i> , 2000, 18, 2250-2256.	1.7	38
353	HIV vaccines "promise and directions": Cooperative research will be good for Australia and the world. <i>Medical Journal of Australia</i> , 1999, 171, 124-125.	0.8	0
354	Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. <i>Immunological Reviews</i> , 1999, 171, 27-44.	2.8	88
355	Can HIV Infection be Prevented with a Vaccine?. <i>Drugs in R and D</i> , 1999, 1, 431-440.	1.1	3
356	A Minimally Replicative HIV-2 Live-Virus Vaccine Protects M. nemestrina from Disease after HIV-2287 Challenge. <i>Virology</i> , 1998, 242, 150-160.	1.1	37
357	Preventive HIV-1 vaccines: where are we going?. <i>International Journal of STD and AIDS</i> , 1998, 9, 715-719.	0.5	2
358	Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus. <i>Journal of Virology</i> , 1998, 72, 10180-10188.	1.5	310
359	Genetically identical primate modelling systems for HIV vaccines. <i>Reproduction, Fertility and Development</i> , 1998, 10, 651.	0.1	5
360	Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cell Responses Correlate with Control of Acute HIV-1 Infection in Macaques. <i>Journal of Infectious Diseases</i> , 1997, 176, 1188-1197.	1.9	48

#	ARTICLE	IF	CITATIONS
361	Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. <i>Aids</i> , 1997, 11, 1565-1574.	1.0	76
362	8.3 Prospects for a preventive HIV vaccine. <i>Medical Journal of Australia</i> , 1996, 165, 212-215.	0.8	2
363	Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. <i>Journal of Virology</i> , 1996, 70, 4941-4947.	1.5	38
364	Cytotoxic and proliferative T cell responses in HIV-1-infected <i>Macaca nemestrina</i> .. <i>Journal of Clinical Investigation</i> , 1995, 95, 248-256.	3.9	29
365	Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 551-560.	0.5	18
366	<i>Listeria monocytogenes</i> peritonitis with review of literature. <i>Australian and New Zealand Journal of Medicine</i> , 1994, 24, 405-405.	0.5	1
367	HIV Infection of monocyte-derived macrophages in vitro reduces phagocytosis of <i>Candida albicans</i> . <i>Journal of Leukocyte Biology</i> , 1994, 56, 318-327.	1.5	66
368	Tuberculous Meningitis: A 30-Year Review. <i>Clinical Infectious Diseases</i> , 1993, 17, 987-994.	2.9	237
369	Oral dapsone versus nebulized pentamidine for <i>Pneumocystis carinii</i> pneumonia prophylaxis. <i>Aids</i> , 1992, 6, 1169-1174.	1.0	36
370	High Precursor Frequency and Promiscuity in β^2 T Cell Receptor Pairing Underpin CD8+ T-Cell Responses to an Immunodominant SARS-CoV-2 Nucleocapsid Epitope. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
371	Re: Integrated Immune Dynamics Define Correlates of COVID-19 Severity and Antibody Responses. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2